253 related articles for article (PubMed ID: 26940270)
1. Lymphoma Microenvironment and Immunotherapy.
Xu ML; Fedoriw Y
Surg Pathol Clin; 2016 Mar; 9(1):93-100. PubMed ID: 26940270
[TBL] [Abstract][Full Text] [Related]
2. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
de Charette M; Houot R
Haematologica; 2018 Aug; 103(8):1256-1268. PubMed ID: 30006449
[TBL] [Abstract][Full Text] [Related]
3. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.
Csizmar CM; Ansell SM
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804869
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in lymphoma.
Ansell SM; Caligaris-Cappio F; Maloney DG
Hematol Oncol; 2017 Jun; 35 Suppl 1():88-91. PubMed ID: 28591421
[No Abstract] [Full Text] [Related]
5. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J; Itzhaki O; Huszar M; Sinai J
Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
[TBL] [Abstract][Full Text] [Related]
8. [The immune microenvironment in malignant lymphoma].
Nishikori M
Rinsho Ketsueki; 2019; 60(9):1229-1235. PubMed ID: 31597848
[TBL] [Abstract][Full Text] [Related]
9. [Development of novel immunotherapy targeting cancer immune evasion].
Tamada K
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicholas NS; Apollonio B; Ramsay AG
Biochim Biophys Acta; 2016 Mar; 1863(3):471-482. PubMed ID: 26554850
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.
Hwang I; Nguyen N
Arch Pharm Res; 2015 Aug; 38(8):1415-33. PubMed ID: 25634101
[TBL] [Abstract][Full Text] [Related]
12. Innate and acquired immune surveillance in the postdissemination phase of metastasis.
Gonzalez H; Robles I; Werb Z
FEBS J; 2018 Feb; 285(4):654-664. PubMed ID: 29131550
[TBL] [Abstract][Full Text] [Related]
13. Genomic alterations underlying immune privilege in malignant lymphomas.
Mottok A; Steidl C
Curr Opin Hematol; 2015 Jul; 22(4):343-54. PubMed ID: 26049756
[TBL] [Abstract][Full Text] [Related]
14. Tumour growth and immune evasion as targets for a new strategy in advanced cancer.
Nicolini A; Ferrari P; Rossi G; Carpi A
Endocr Relat Cancer; 2018 Nov; 25(11):R577–R604. PubMed ID: 30306784
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Tumor Microenvironment of Leukemia and Lymphoma.
Höpken UE; Rehm A
Trends Cancer; 2019 Jun; 5(6):351-364. PubMed ID: 31208697
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeted therapy for malignant lymphoma.
Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
[TBL] [Abstract][Full Text] [Related]
17. Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis.
De Paoli P; Carbone A
Semin Cancer Biol; 2015 Oct; 34():70-80. PubMed ID: 25837157
[TBL] [Abstract][Full Text] [Related]
18. Galectin 3 as a guardian of the tumor microenvironment.
Ruvolo PP
Biochim Biophys Acta; 2016 Mar; 1863(3):427-437. PubMed ID: 26264495
[TBL] [Abstract][Full Text] [Related]
19. Role of m
Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
[TBL] [Abstract][Full Text] [Related]
20. The tumor microenvironment in follicular lymphoma.
Yang ZZ; Ansell SM
Clin Adv Hematol Oncol; 2012 Dec; 10(12):810-8. PubMed ID: 23271353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
